<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)
NOVITRON INTERNATIONAL, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.01 par value per share
--------------------------------------
(Title of Class of Securities)
670088103
---------
(CUSIP Number)
Third Security, LLC
The Governor Tyler
1902 Downey Street
Radford, Virginia 24141
Attention: Marcus E. Smith, Esq.
Telephone No.: 540-633-7971
---------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
Copy to:
John Owen Gwathmey, Esq.
Hunton & Williams
Riverfront Plaza, East Tower
951 East Byrd Street
Richmond, Virginia 23219
December 31, 2000
-----------------
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition which is the
subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1(e), (f) or (g),
check the following box [_].
Page 1 of 10 Pages
<PAGE>
-------------------------- ------------------------
CUSIP NO. 670088103 13D Page 2 of 10 Pages
-------------------------- ------------------------
------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Randal J, Kirk
------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3 SEC USE ONLY
------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
302,232
SHARES -----------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 99,801
-----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
302,232
PERSON -----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
WITH
99,801
------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
402,033
------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.8%
------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
------------------------------------------------------------------------------
<PAGE>
-------------------------- ------------------------
CUSIP NO. 670088103 13D Page 3 of 10 Pages
-------------------------- ------------------------
------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
Clinical Chemistry Holdings, Inc. I.R.S. Identification No.:52-2202556
------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3 SEC USE ONLY
------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
0
SHARES -----------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
-----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
0
PERSON -----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
WITH
0
------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUEDS CERTAIN SHARES
[_]
------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
------------------------------------------------------------------------------
<PAGE>
-------------------------- ------------------------
CUSIP NO. 670088103 13D Page 4 of 10 Pages
-------------------------- ------------------------
------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
RJK, L.L.C. I.R.S. Identification No.: 54-1816015
------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3 SEC USE ONLY
------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Virginia
------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
0
SHARES -----------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 99,801
-----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
0
PERSON -----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
WITH
99,801
------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
99,801
------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.9%
------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO - limited liability company
------------------------------------------------------------------------------
<PAGE>
This Amendment No. 3 (the "Amendment") amends and supplements the Statement
on Schedule 13D, dated November 26, 1999 and filed on December 6, 1999, as
amended by Amendment No. 1 dated March 10, 2000 and filed on March 15, 2000 and
Amendment No. 2 dated June 8, 2000 and filed on June 9, 2000 (the "Original
Schedule 13D"), relating to the Common Stock, par value $.01 per share (the
"Common Stock"), of Novitron International, Inc., a Delaware corporation (the
"Issuer"). Mr. Randal J. Kirk ("Mr. Kirk"), Clinical Chemistry Holdings, Inc.,
a Delaware corporation that is controlled by Mr. Kirk ("CCH"), and RJK, L.L.C.,
a Virginia limited liability company that is controlled by Mr. Kirk ("RJK" and,
together with Mr. Kirk and CCH, the "Reporting Persons"), are filing this
Amendment to update the information in the Original Schedule 13D with respect to
the beneficial ownership of the Common Stock by the Reporting Persons. As
described in this Amendment, some of the Common Stock that is beneficially owned
by Mr. Kirk is directly beneficially owned by one of the following entities,
each of which is controlled by Mr. Kirk: Kirkfield, L.L.C., a Virginia limited
liability company, and Zhong Mei, L.L.C., a Virginia limited liability company.
Item 2. Identity and Background
-----------------------
Items 2(a)-(c) of the Original Schedule 13D are amended to read in their
entirety as follows:
"This statement is being filed on behalf of Mr. Randal J. Kirk ("Mr.
Kirk"), Clinical Chemistry Holdings, Inc., a Delaware corporation that is
controlled by Mr. Kirk ("CCH"), and RJK, L.L.C., a Virginia limited liability
company that is controlled by Mr. Kirk ("RJK" and, together with Mr. Kirk, the
"Reporting Persons"). The principal occupation/employment of Mr. Kirk is
investor. The business address of Mr. Kirk is c/o Third Security, LLC, The
Governor Tyler, 1902 Downey Street, Radford, Virginia 24141. CCH is a holding
company for a variety of clinical chemistry-related businesses, including its
wholly-owned subsidiaries Landmark Scientific, Inc. and Landmark Export
Corporation. The address of CCH's principal business and office is 101-B
Creekridge Road, Greensboro, North Carolina 27406. The name, address and present
principal occupation of each of the directors and executive officers of CCH are
set forth in Appendix A attached hereto. The principal business of RJK is
investment. The address of RJK's principal business and office is The Governor
Tyler, 1902 Downey Street, Radford, Virginia 24141. Mr. Kirk is the sole manager
of RJK."
Item 3. Source and Amount of Funds or Other Consideration.
--------------------------------------------------
Item 3 of the Original Schedule 13D is hereby amended and supplemented as
follows:
"On November 28, 2000, Kirkfield used approximately $1,032 of working
capital to purchase 500 shares of Common Stock. On December 4, 2000, Kirkfield
used approximately $408 of working capital to purchase 200 shares of Common
Stock. On December 8, 2000, Kirkfield used approximately $416 of working
capital to purchase 200 shares of Common Stock. On December 31, 2000, CCH sold
all 398,133 shares of Common Stock directly beneficially owned by it as follows:
239,269 shares to Mr. Kirk for $690,734; 49,780 shares to Kirkfield for
Page 5 of 10 Pages
<PAGE>
$143,707; 99,801 shares to RJK for $288,110; and 9,283 shares to Zhong Mei,
L.L.C., a Virginia limited liability company controlled by Mr. Kirk ("Zhong
Mei"), for $26,799."
Item 5. Interest in Securities of the Issuer.
-------------------------------------
Item 5(a) of the Original Schedule 13D is hereby amended to read in its
entirety as follows:
"The aggregate number and percentage of shares of Common Stock to
which this statement relates is 402,033 shares, representing 27.8% of the
1,445,227 shares outstanding as reported by the Issuer on November 13, 2000 in
the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30,
2000 (the most recent available filing by the Issuer with the Securities and
Exchange Commission). Mr. Kirk directly beneficially owns 239,269 of the shares
to which this statement relates. Kirkfield, RJK and Zhong Mei directly
beneficially own 53,680, 99,801 and 9,283 shares, respectively, to which this
statement relates. Mr. Kirk could be deemed to have indirect beneficial
ownership of the shares directly beneficially owned by Kirkfield, RJK and Zhong
Mei."
Item 5(b) of the Original Schedule 13D is hereby amended to read in its
entirety as follows:
"Mr. Kirk has the sole power to vote or direct the vote and the sole
power to dispose or to direct the disposition of the shares of Common Stock
reported as directly beneficially owned by him in Item 5(a) hereof and the
shares of Common Stock reported as being directly beneficially owned by
Kirkfield and Zhong Mei in Item 5(a) hereof. Mr. Kirk has, together with RJK,
the shared power to vote or direct the vote and the shared power to dispose or
to direct the disposition of shares of Common Stock reported as directly
beneficially owned by RJK in Item 5(a) hereof."
Item 5(c) of the Original Schedule 13D is hereby amended and supplemented
as follows:
"The following table lists all transactions in shares of Common Stock
by the Reporting Persons that were effected during the period from June 9, 2000,
the date on which Amendment No. 2 to this statement was originally filed with
the Securities and Exchange Commission, through January 7, 2001. Unless
otherwise indicated, all such transactions were effected on The Nasdaq SmallCap
Market.
<TABLE>
<CAPTION>
Shares Purchased Average Price
Reporting Person Date (Sold) Per Share*
-------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Mr. Kirk (Kirkfield) 11/28/00 500 $1.98
Mr. Kirk (Kirkfield) 12/4/00 200 $1.94
Mr. Kirk (Kirkfield) 12/8/00 200 $1.98
CCH 12/31/00 (398,133)** $2.89
Mr. Kirk 12/31/00 239,269** $2.89
Mr. Kirk (Kirkfield) 12/31/00 49,780** $2.89
</TABLE>
Page 6 of 10 pages
<PAGE>
<TABLE>
<CAPTION>
Shares Purchased Average Price
Reporting Person Date (Sold) Per Share
-------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
RJK 12/31/00 99,801** $2.89
Mr. Kirk (Zhong Mei) 12/31/00 9,283** $2.89
</TABLE>
* Price excludes commission.
** CCH sold 398,133 shares to Mr. Kirk (239,269 shares), Kirkfield (49,780
shares), RJK (99,801 shares) and Zhong Mei (9,283 shares).
Item 5(e) of the Original Schedule 13D is hereby amended to read in its
entirety as follows:
"CCH ceased to be the beneficial owner of more than five percent of the
shares of Common Stock on December 31, 2000."
Item 7 Material to be Filed as Exhibits.
---------------------------------
The following document is being filed as an exhibit to this Amendment and
is incorporated herein by reference:
Exhibit 7. Joint Filing Agreement.
Page 7 of 10 Pages
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of their knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Date: January 8, 2001 /s/ Randal J. Kirk
------------------------------------------
Randal J. Kirk
Date: January 8, 2001 CLINICAL CHEMISTRY HOLDINGS, INC.
By: /s/ Audrey Ho Ping Ting
-------------------------------------
Audrey Ho Ping Ting
President and Chief Executive Officer
Date: January 8, 2001 RJK, L.L.C.
By: /s/ Randal J. Kirk
-------------------------------------
Randal J. Kirk
Manager
Page 8 of 10 Pages
<PAGE>
EXHIBIT INDEX
-------------
Exhibit Number Exhibit
-------------- -------
Exhibit 7. Joint Filing Agreement.
Page 9 of 10 Pages
